|
| Viekira Pak治疗基因Ⅰ型慢性丙型肝炎的进展 |
| Latest Development of Viekira Pak, a Drug Against Chronic HCV Patients with Genotype Ⅰ |
| |
| DOI： |
| 中文关键词: 帕利瑞韦 奥毕他韦 达萨布韦 利托那韦 丙型肝炎 |
| 英文关键词:Paritaprevir Ombitasvir Dasabuvir Ritonavir HCV |
| 基金项目: |
|
| 摘要点击次数: 869 |
| 全文下载次数: 918 |
| 中文摘要: |
| 摘 要Viekira Pak是由帕利瑞韦（paritaprevir）、奥毕他韦（ombitasvir）、达萨布韦（dasabuvir）和利托那韦组成的复方制剂。由于本品能同时抑制NS3/4A、NS5A、NS5B四个非结构蛋白，对于丙型肝炎病毒（HCV）繁殖周期进行了全覆盖，从而增加抑制HCV能力，减少其耐药性的概率。临床试验证明对于HCV基因Ⅰa、Ⅰb型患者都有疗效，无论他们是初次治疗、还是复治、或者有无肝硬化并发症疗效都很明显。但是对于基因Ⅰa型、有肝硬化并发症的Ⅰb患者，本品还需要与利巴韦林合用，才能产生好的疗效，这可能会限制本品的应用。 |
| 英文摘要: |
| ABSTRACTViekira Pak was composed of paritaprevir, ombitasvir,dasabuvir,ritonavir. It was able to inhibit four kinds of nonstructural protein NS3/4A，NS5A，NS5B, therefore, this combination was designed to target multiple steps in the HCV lifecycle and reduced its resistance. The clinical trials had proved that it was effective against HCV patients with both noncirrhotic and cirrhotic complication. However, as for HCV patients with genotype Ⅰa or genotype Ⅰb with cirrhotic complication, Viekira Pak should be used with ribavirin, which might limited its use in practice. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
